EpiCept Announces Resignation of Board Member Gert Caspritz

EpiCept Announces Resignation of Board Member Gert Caspritz

    TARRYTOWN, N.Y.--(BUSINESS WIRE)--March 5, 2008--Regulatory News:

    EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today
announced that Gert Caspritz has resigned from the Company's Board of
Directors, effective March 6, 2008. Dr. Caspritz, a general partner of
TVM Capital, has been a member of the Company's Board since 1999 and
served as EpiCept's Chairman from July 2002 until December 2004."On behalf of EpiCept and its shareholders, I would like to thank
Gert for his many contributions to the Company and its Board of
Directors. TVM was one of the founding venture capital investors in
EpiCept and we appreciate their loyal support during the time when we
were a private company, and Gert's ongoing contributions as a Board
member as a public company. We completely understand that he needs to
devote his energies going forward towards the portfolio of private
equity investments that he directly oversees," remarked Jack Talley,
President and CEO of EpiCept.

    About EpiCept Corporation

    EpiCept is focused on unmet needs in the treatment of pain and
cancer. The Company's broad portfolio of pharmaceutical product
candidates includes several pain therapies in clinical development and
a lead oncology compound for AML with demonstrated efficacy in a Phase
III trial; a marketing authorization application for this compound is
approaching a decision in Europe. In addition, EpiCept's ASAP
technology, a proprietary live cell high-throughput caspase-3
screening technology, can efficiently identify new cancer drug
candidates and molecular targets that selectively induce apoptosis in
cancer cells. Two oncology drug candidates currently in clinical
development that were discovered using this technology have also been
shown to act as vascular disruption agents in a variety of solid
tumors.

    Forward-Looking Statements

    This news release and any oral statements made with respect to the
information contained in this news release, contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Such forward-looking statements include statements
which express plans, anticipation, intent, contingency, goals,
targets, future development and are otherwise not statements of
historical fact. These statements are based on EpiCept's current
expectations and are subject to risks and uncertainties that could
cause actual results or developments to be materially different from
historical results or from any future results expressed or implied by
such forward-looking statements. Factors that may cause actual results
or developments to differ materially include: the risk that Ceplene
will not receive regulatory approval or marketing authorization in the
EU or that any appeal of an adverse decision in the EU will not be
successful, the risk that Ceplene, if approved, will not achieve
significant commercial success, the risks associated with our need to
raise additional financing to continue to meet our capital needs and
our ability to continue as a going concern, the risk that Myriad's
development of Azixa will not be successful, the risk that Azixa(TM)
will not receive regulatory approval or achieve significant commercial
success, the risk that we will not receive any significant payments
under our agreement with Myriad, the risk that the development of our
other apoptosis product candidates will not be successful, the risk
that our ASAP technology will not yield any successful product
candidates, the risk that clinical trials for NP-1 or EPC 2407 will
not be successful, that NP-1 or EPC 2407 will not receive regulatory
approval or achieve significant commercial success, the risk that our
other product candidates that appeared promising in early research and
clinical trials do not demonstrate safety and/or efficacy in
larger-scale or later stage clinical trials, the risk that EpiCept
will not obtain approval to market any of its product candidates, the
risks associated with dependence upon key personnel, the risks
associated with reliance on collaborative partners and others for
further clinical trials, development, manufacturing and
commercialization of our product candidates; the cost, delays and
uncertainties associated with our scientific research, product
development, clinical trials and regulatory approval process; our
history of operating losses since our inception; competition;
litigation; risks associated with prior material weaknesses in our
internal controls; and risks associated with our ability to protect
our intellectual property. These factors and other material risks are
more fully discussed in EpiCept's periodic reports, including its
reports on Forms 8-K, 10-Q and 10-K and other filings with the U.S.
Securities and Exchange Commission. You are urged to carefully review
and consider the disclosures found in EpiCept's filings which are
available at www.sec.gov or at www.epicept.com. You are cautioned not
to place undue reliance on any forward-looking statements, any of
which could turn out to be wrong due to inaccurate assumptions,
unknown risks or uncertainties or other risk factors.

    EPCT-GEN

    *Azixa is a registered trademark of Myriad Genetics, Inc.


    CONTACT: EpiCept Corporation:
             Robert W. Cook, 914-606-3500
             rcook@epicept.com
             or
             Media:
             Feinstein Kean Healthcare
             Greg Kelley, 617-577-8110
             gregory.kelley@fkhealth.com
             or
             Investors:
             Lippert/Heilshorn & Associates
             Kim Sutton Golodetz, 212-838-3777
             kgolodetz@lhai.com
             or  Bruce Voss, 310-691-7100
             bvoss@lhai.com